Scarica l'app Stockscreener
9.20
1.18%
-0.11
Dopo l'orario di chiusura:
9.25
0.05
+0.54%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Precedente Chiudi:
$9.31
Aprire:
$9.5
Volume 24 ore:
2.40M
Relative Volume:
0.86
Capitalizzazione di mercato:
$1.05B
Reddito:
-
Utile/perdita netta:
$-294.51M
Rapporto P/E:
-2.5843
EPS:
-3.56
Flusso di cassa netto:
$-244.42M
1 W Prestazione:
-0.11%
1M Prestazione:
-3.87%
6M Prestazione:
-32.05%
1 anno Prestazione:
-78.52%
Intervallo 1D:
$8.88
$9.54
Intervallo di 1 settimana:
$8.88
$10.23
Portata 52W:
$6.36
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Nome
Dyne Therapeutics Inc
Settore
Industria
Telefono
(781) 786-8230
Indirizzo
1560 TRAPELO ROAD, WALTHAM
Confronta DYN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
9.20 | 1.32B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-24 | Iniziato | Bernstein | Mkt Perform |
| 2025-06-11 | Ripresa | Raymond James | Outperform |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-10-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Reiterato | Chardan Capital Markets | Buy |
| 2024-04-30 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-20 | Iniziato | H.C. Wainwright | Buy |
| 2023-02-27 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Iniziato | Oppenheimer | Outperform |
| 2023-01-26 | Iniziato | Guggenheim | Buy |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Outperform |
| 2020-10-12 | Iniziato | JP Morgan | Overweight |
| 2020-10-12 | Iniziato | Jefferies | Buy |
| 2020-10-12 | Iniziato | Piper Sandler | Overweight |
| 2020-10-12 | Iniziato | Stifel | Buy |
Mostra tutto
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss - Benzinga
Can Dyne Deliver And Achieve Milestones In DMD And Myotonic Dystrophy Trials? - RTTNews
How many analysts rate Dyne Therapeutics Inc. as a “Buy”Market Forecast Recommendation With Low Risk - jammulinksnews.com
Dyne Therapeutics Advances in Neuromuscular Therapies - TipRanks
Dyne Therapeutics Narrowed Its Loss And Won Analyst Support - Finimize
Dyne Therapeutics: A High-Conviction Biotech Play with Near-Term Catalysts and a Strengthened Balance Sheet - AInvest
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Dyne Therapeutics extends cash runway as it advances key drug programs - Investing.com Australia
Dyne Therapeutics, Inc. Q2 Loss Increases, Misses Estimates - Nasdaq
Dyne (DYN) Expects Funding to Sustain Operations Through 2027 - GuruFocus
Dyne (DYN) Advances Clinical Programs and Strengthens Financial Position - GuruFocus
Dyne Therapeutics Extends Cash Runway to Q3 2027, Advances Clinical Trials for DM1 and DMD - Quiver Quantitative
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | DYN Stock News - GuruFocus
What are analysts’ price targets for Dyne Therapeutics Inc. in the next 12 monthsBuild wealth steadily with smart trading - jammulinksnews.com
What is the dividend policy of Dyne Therapeutics Inc. stockOutstanding capital appreciation - jammulinksnews.com
What is the risk reward ratio of investing in Dyne Therapeutics Inc. stockDiscover breakthrough investment opportunities - jammulinksnews.com
Why is Dyne Therapeutics Inc. stock attracting strong analyst attentionUnlock exclusive trading strategies for gains - jammulinksnews.com
What is Dyne Therapeutics Inc. company’s growth strategyDiscover market opportunities with expert help - jammulinksnews.com
Should I hold or sell Dyne Therapeutics Inc. stock in 2025Breakthrough investment results - jammulinksnews.com
What makes Dyne Therapeutics Inc. stock price move sharplyRecord-setting profit potential - jammulinksnews.com
What are the technical indicators suggesting about Dyne Therapeutics Inc.Track emerging stocks with high growth potential - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - WV News
Dyne Therapeutics Inc. Stock Analysis and ForecastBreakout profit opportunities - Autocar Professional
What analysts say about Dyne Therapeutics Inc. stockFree Stock Market Return Analysis - Autocar Professional
What drives Dyne Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
Is Dyne Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional
Dyne Therapeutics (NASDAQ:DYN) Price Target Lowered to $9.00 at JPMorgan Chase & Co. - MarketBeat
Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Ray Dalio, Scott Bessent, Elliott Management, Citadel Investment Group, Balyasny Asset Management, Qualys Inc (QLYS), Dyne Therapeutics Inc (DYN), and More - Insider Monkey
Dyne Therapeutics Inc Azioni (DYN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
10.28%
2.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):